Brooks Laboratories Limited (BROOKS) - Total Assets
Based on the latest financial reports, Brooks Laboratories Limited (BROOKS) holds total assets worth Rs1.40 Billion INR (≈ $15.13 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Brooks Laboratories Limited book value and equity for net asset value and shareholders' equity analysis.
Brooks Laboratories Limited - Total Assets Trend (2007–2025)
This chart illustrates how Brooks Laboratories Limited's total assets have evolved over time, based on quarterly financial data.
Brooks Laboratories Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Brooks Laboratories Limited's total assets of Rs1.40 Billion consist of 27.4% current assets and 72.6% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.0% |
| Accounts Receivable | Rs199.92 Million | 16.2% |
| Inventory | Rs92.05 Million | 7.4% |
| Property, Plant & Equipment | Rs139.72 Million | 11.3% |
| Intangible Assets | Rs91.00K | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Brooks Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Brooks Laboratories Limited market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Brooks Laboratories Limited's current assets represent 27.4% of total assets in 2025, a decrease from 43.5% in 2007.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2025, down from 1.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 16.2% of total assets.
Brooks Laboratories Limited Competitors by Total Assets
Key competitors of Brooks Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Brooks Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.73 | 1.32 | 0.93 |
| Quick Ratio | 1.38 | 0.99 | 0.46 |
| Cash Ratio | 0.00 | 0.01 | 0.00 |
| Working Capital | Rs159.30 Million | Rs91.66 Million | Rs-44.99 Million |
Brooks Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Brooks Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 36.8% |
| Total Assets | Rs1.24 Billion |
| Market Capitalization | $17.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Brooks Laboratories Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Brooks Laboratories Limited's assets grew by 36.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Brooks Laboratories Limited (2007–2025)
The table below shows the annual total assets of Brooks Laboratories Limited from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs1.24 Billion ≈ $13.38 Million |
+36.76% |
| 2024-03-31 | Rs904.45 Million ≈ $9.78 Million |
-17.47% |
| 2023-03-31 | Rs1.10 Billion ≈ $11.85 Million |
-44.06% |
| 2022-03-31 | Rs1.96 Billion ≈ $21.19 Million |
+20.87% |
| 2021-03-31 | Rs1.62 Billion ≈ $17.53 Million |
+2.67% |
| 2020-03-31 | Rs1.58 Billion ≈ $17.07 Million |
-6.01% |
| 2019-03-31 | Rs1.68 Billion ≈ $18.16 Million |
-2.73% |
| 2018-03-31 | Rs1.73 Billion ≈ $18.67 Million |
+5.87% |
| 2017-03-31 | Rs1.63 Billion ≈ $17.64 Million |
+6.92% |
| 2016-03-31 | Rs1.53 Billion ≈ $16.50 Million |
+12.87% |
| 2015-03-31 | Rs1.35 Billion ≈ $14.62 Million |
-3.77% |
| 2014-03-31 | Rs1.40 Billion ≈ $15.19 Million |
+6.67% |
| 2013-03-31 | Rs1.32 Billion ≈ $14.24 Million |
+24.44% |
| 2012-03-31 | Rs1.06 Billion ≈ $11.44 Million |
+158.92% |
| 2011-03-31 | Rs408.64 Million ≈ $4.42 Million |
+9.68% |
| 2010-03-31 | Rs372.57 Million ≈ $4.03 Million |
+16.00% |
| 2009-03-31 | Rs321.19 Million ≈ $3.47 Million |
+26.54% |
| 2008-03-31 | Rs253.81 Million ≈ $2.74 Million |
+69.46% |
| 2007-03-31 | Rs149.78 Million ≈ $1.62 Million |
-- |
About Brooks Laboratories Limited
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and d… Read more